ReviewCancer immunology, immunotherapy : CII2008
Anti-cancer therapies targeting the tumor stroma.
Review in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 155 citations in OpenAlex.
- Trial
- The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer.NPJ precision oncology · 2025Review
- Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination.Cancer metastasis reviews · 2024Review
- Prognostic value of integrin αV expression and localization pattern in invasive breast carcinomas.Neoplasia (New York, N.Y.) · 2022Article
- Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.Biophysical reviews · 2022Review
- Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation.Scientific reports · 2021Article
- Harnessing molecular recognition for localized drug delivery.Advanced drug delivery reviews · 2021Review
- Ultrasmall BiOI Quantum Dots with Efficient Renal Clearance for Enhanced Radiotherapy of Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Pro-inflammatory macrophage polarization enhances the anti-cancer efficacy of self-assembled galactomannan nanoparticles entrapped with hydrazinocurcumin.Drug delivery and translational research · 2019Article
- Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer.Oncology letters · 2019Review
- Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.Frontiers in oncology · 2019Article
- Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.Nature communications · 2018Article
- Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.Pathology oncology research : POR · 2018Article
- Isolation and characterization of equine native MSC populations.Stem cell research & therapy · 2017Article
- Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.Cancers · 2017Review
- Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy.International journal of molecular sciences · 2017Review
- Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Advances in experimental medicine and biology · 2017Review
- Genetically modified mesenchymal stromal cells in cancer therapy.Cytotherapy · 2016Review
- In vitro models of cancer stem cells and clinical applications.BMC cancer · 2016Review
- A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.International journal of cancer · 2016Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For anti-tumor therapy different strategies have been employed, e.g., radiotherapy, chemotherapy, or immunotherapy. Notably, these approaches do not only address the tumor cells themselves, but also the tumor stroma cells, e.g., endothelial cells, fibroblasts, and macrophages. This is of advantage, since these cells actively contribute to the proliferative and invasive behavior of the tumor cells via secretion of growth factors, angiogenic factors, cytokines, and proteolytic enzymes. In addition, tumor stroma cells take part in immune evasion mechanisms of cancer. Thus, approaches targeting the tumor stroma attract increasing attention as anti-cancer therapy. Several molecules including growth factors (e.g., VEGF, CTGF), growth factor receptors (CD105, VEGFRs), adhesion molecules (alphavbeta3 integrin), and enzymes (CAIX, FAPalpha, MMPs, PSMA, uPA) are induced or upregulated in the tumor microenvironment which are otherwise characterized by a restricted expression pattern in differentiated tissues. Consequently, these molecules can be targeted by inhibitors as well as by active and passive immunotherapy to treat cancer. Here we discuss the results of these approaches tested in preclinical models and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.